Antimicrobial activity of Ro 19-5247 (T-2525), a new oral cephalosporin, tested against 7,745 recent clinical isolates.
The susceptibility testing of 7,745 recent clinical isolates from four medical centers showed Ro 19-5247 to be eight- to greater than 64-fold more active than cephalexin against the Enterobacteriaceae. Ro 19-5247 was comparable with cephalexin in anti-staphylococcal activity (MIC50, 4.0 micrograms/ml) and fourfold more active than cefixime. None of the oral cephalosporins were effective (MIC50, greater than 32 micrograms/ml) against enterococci, Pseudomonas aeruginosa and P. maltophilia. beta-lactamase hydrolysis experiments failed to demonstrate significant Ro 19-5247 inactivation by ten commonly encountered chromosomal- or plasmid-mediated enzymes (P99, K1, K14, TEM, CARB, OXA).
D001419:Bacteria / Q000187:drug effects*; D020682:Cefixime; D015281:Cefmenoxime / Q000031:analogs & derivatives*; D002439:Cefotaxime / Q000031:analogs & derivatives / Q000494:pharmacology; D002506:Cephalexin / Q000494:pharmacology; D002509:Cephaloridine / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects; D008826:Microbial Sensitivity Tests
D002511:Cephalosporins; C049493:cefteram; D020682:Cefixime; D015281:Cefmenoxime; D002509:Cephaloridine; D002439:Cefotaxime; D002506:Cephalexin